Group 1 - The core viewpoint of the article highlights that Hansa Biopharma-B (03378) has seen a significant decline in its stock price, dropping over 13% and reaching a new low of 15.05 HKD, which is more than a 50% decrease from its IPO price of 32 HKD [1] - As of the report, the stock is down 13.4%, trading at 15.06 HKD, with a trading volume of 17.4468 million HKD and a total market capitalization of 2.061 billion HKD [1] - Hansa Biopharma is a biotechnology company specializing in structural biology, translational medicine, and clinical development, with three clinical-stage candidates in oncology and seven preclinical candidates in development [1] Group 2 - The company's core product, HX009, is a self-developed dual-function antibody fusion protein targeting PD-1 (an immune checkpoint receptor) and SIRPα [1] - It is noteworthy that none of Hansa Biopharma's pipeline products have achieved commercialization [1] - Financially, the company reported losses of 85.16 million HKD, 117 million HKD, and 87.438 million HKD for the first eight months of 2023, 2024, and 2025, respectively [1] - As of October 31, 2025, the company has cash and cash equivalents amounting to 133 million HKD, with total current liabilities of 220 million HKD [1]
港股异动 | 翰思艾泰-B(03378)跌超13% 较招股价已腰斩 总市值约20亿港元